Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 1, Issue 4, 2009, Pages 415-425

  Bisht, Savita ^a,b   Maitra, Amarnath ^a  

^a UNIVERSITY OF DELHI   (India)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPEUTIC AGENTS; CHITOSAN NANOPARTICLES; ENHANCED PERMEABILITY AND RETENTION EFFECTS; HYDROGEL NANOPARTICLES; INTERSTITIAL FLUIDS; TARGETED DELIVERY; TARGETED DRUG DELIVERY; TUMOR VASCULATURE;

CHEMOTHERAPY; CHITOSAN; DEXTRAN; DISEASES; DRUG DELIVERY; HYDROGELS; NANOPARTICLES;

TUMORS;

ANTINEOPLASTIC ANTIBIOTIC; CHITOSAN; DEXTRAN; DOXORUBICIN; NANOPARTICLE;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CHITOSAN; DEXTRANS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 74149088191     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.43     Document Type: Article

References (71)

1. Seymour WL. Systemic cancer therapy using polymerbased prodrugs and progenies. In: Dumitriu S, ed. Polymeric Biomaterials. 2nd edition, NY, Marcel-Dekker, Inc.; 2001, 843.
2. Beardsle y T. A war not won. Sci Amer 1994, 270(1):130.
3. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003, 20(9):1337Sept.
4. Hartman KB, Wilson LJ, Rosenblum MG. Detecting and treating cancer with nanotechnology. Mol Diagn Ther 2008, 12(1):1.
5. Yu M, Dai M, Liu Q, Xiu R. Alternative formulations of paclitaxel. Cancer Treat Rev 1997, 23(2):87.
6. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002, 28(A):3AprilSuppl Review.
7. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 2002, 28(A):7April Suppl Review.
8. Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends. Front Biosci 2008, 13:2744January.
9. Brigger I, Dubernet C, Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54(5):631.
10. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55(3):329February.
11. Roco MC. Converging technologies: nanotechnology and biomedicine. Converging technologies for Improving Human Performance. National Science Foundation, US Department of Commerce Report, Washington D.C. 2002, Biomedical Nanotechnology, CRC Press, 2005.
12. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007, 7(11):850December.
13. Ortho Biotech Product. L.P. 2003-2008. Liposomal Doxorubicin, http://www.cancerbackup. org.uk/Treatments/Chemotherapy/Individual drugs/Liposomal doxorubicin.
14. Wyeth Pharmaceutics Inc. Rapamune? (sirolimus) http://www.wyeth.com/world wide.
15. MaedaH,Wu J, Sawa T,Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271.
16. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, et al. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular carrier. Eur J Cancer 1995, 31A:766.
17. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomed 2007, 2(6):789Review.
18. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47(12):3039.
19. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752.
20. Duncan R. Polymer conjugates for tumor targeting and intercytoplasmic delivery: the EPR effect as a common gateway?. Pharm Sci Technol Today 1999, 2(11):441.
21. Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Target 1996, 3(5):375.
22. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics:advantages and prospects with special emphasis on solid tumor targeting. Clin Pharmacokinet 2003, 42(13):1089.
23. Carter SK. Adriamycin-thoughts for the future. Cancer Chemother Rep 1975, 63:1877.
24. Young C, Ozols RF, Myers CE. The anthracycline anti neoplastic drugs. N Engl J Med 1981, 305:139.
25. Rahman A, Joher A, Neefe JR. Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Br J Cancer 1986, 54:401.
26. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 1990, 27:13.
27. Kwon JS, Kopecek J. Diblock polymeric nanoparticles for drug delivery. Crit Rev Ther Drug Carrier Syst 1998, 15(5):481.
28. Mitra AN, De TK, Maitra S. Hydrogel nanoparticles: applications in drug delivery. Somasundaram P Hubbard A, Eds. Encyclopedia of Surface and Colloid Science, 2nd ed. Taylor and Francis, London, 2006, 2821.
29. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomed 2007, 2(2):219April.
30. Janes KA, Fresneau MP,Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 2001, 73:255.
31. Yu JJ, Lee HA, Kim JH, Kong WH, Kim Y, et al. Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin. JDrug Target 2007, 15(4):279.
32. Zhang J, Chen XG, Li YY, Liu CS. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomed 2007, 3(4):258.
33. Levi-Schaffer F, Bernstein A, Meshorer A, Arnon R. Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat Rep 1982, 66:107.
34. Bernstein A, Hurwitz E, Marnon R, Arnon R, Sela M, et al. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J Natl Cancer Inst 1978, 60:379.
35. Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr Pharm Biotechnol 2003, 4(5):283Review.
36. Aspinall GO. The polysaccharides 35. New York: Academic Press, 1982In:, Vol. I.
37. LamW, ChanH, YangM, Cheng S, Fong W. Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma cells. Anticancer drugs 1999, 10(2):171.
38. Sheldon K, Marks A, Baumal R. Sensitivity of multidrug resistant KB-C1 cells to an antibody-dextranadriamycin conjugate. Anticancer Res 1989, 9(3):637.
39. Lam W, Leung CH, Chan HL, Fong WF. Toxicity and DNA binding of dextran-doxorubicin conjugatesinmultidrug-resistant KB-V1 cells: optimization of dextran size. Anticancer Drugs 2000, 11(5):377June.
40. Guu JA, Hsiue GH, Juang TM. Synthesis and biological properties of antitumor-active conjugates of ADR with dextran. J Biomater Sci Polym Ed 2002, 13(10):1135.
41. Ueda Y, Kikukawa A, Munechika K, Yamanouchi K, Yokoyama K. Comparative distribution of adriamycin linked to oxidized dextran and free adriamycin in tumorbearing animals. Proc Int Sympos Control Rel Bioactive Mater 1989, 16:142.
42. Ueda Y, Munechika K, Kikukawa A, Kanoh Y, Yamanouchi K, et al. Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamyein linked to oxidized dextran in rats. Chem Pharm Bull (Tokyo) 1989, 37(6):1639June.
43. Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993, 11:187.
44. Kikukawa A, Munechika K, Ueda Y, Yamanouchi K, Yokoyama K, et al. Tissue concentration of adriamycin and adriamycin oxidized dextran conjugate in tumor bearing rats and mice. Drug Deliv Syst 1990, 5:255.
45. Munechika K, Sogame Y, Kishi N, Kawabata Y, Ueda Y, et al. Tissue distribution of macromolecular conjugate, adriamycin linked to oxidized dextran in rat and mouse bearing tumor cells. Biol Pharm Bull 1994, 17(9):1193 September.
46. Sogame Y, Munechika K, Kawabata Y, Ueda Y, Tsuda Y, et al. Distribution of adriamycin oxidized dextran conjugate (ADM-OXD) in tumor-bearing rats. Drug Deliv Syst 1992, 7:181.
47. Yokoyama K, Ueda Y, Kikukawa A, Yamanouchi K. Drug delivery systems: the industrial view. In Targeting of Drugs. Gregoriadis G, Ed. New York: Plenum Press, 1990, 137-153.
48. Munechika K, Nakae T, Kikukawa A, Ueda Y, Yamanouchi K, et al. Intracellular behavior of adriamycin-oxidized dextran conjugate. Drug Deliv Syst 1991, 6:127.
49. Kumazawa E, Ochi Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. Cancer Sci 2004, 95(2):168.
50. Takimoto CHM, Forero L, Schwartz GH, et al. A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Proc Am Soc Clin Oncol 2003, 22:130 (Abstract 522).
51. Crepon B, Jozefonvicz J, Chytry V, Rihov̀a B, Kopecek J: Enzymatic degradation and immunogenic properties of derivatized dextrans. Biomaterials 1991, 12(6):550.
52. Grislain L, Couvreur P, Lenaerts V, Roland M, Depreze Decampeneere D, et al. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 1983, 15:335.
53. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed 2006, 1(4):417 Review.
54. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol 1990, 26:13.
55. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, et al. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J PharmSci 1980, 69:199.
56. Chiannilkulchai N, Ammoury N, Caillou B, De- vissaguet JPh, Couvreur P. Hepatic tissue distribution of doxoru- bicin-loaded particles after i.v. administration in reticulosar- coma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol 1990, 26:122.
57. Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells it in vitro. J Control Release 2000, 68:283.
58. Rolland A: Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline. Int J Pharm1989, 54:113.
59. Kattan J, Droz JP, Couvreur P, Marino JP, Laroze A, et al. Phase I clinical trial and phar macokinetics evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs 1992, 10:191Boutantumor.
60. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42(6):463.
61. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. OccupMed (Lond) 2006, 56(5):307 Review.
62. Maeda H, Seymour LW, Miyamoto Y. Conjugation of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3:357.
63. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra AN, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000, 202:1.
64. Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, et al. Novel taxol formulation: polyvinylpyrrolidone nanoparticles-encapsulated taxol for drug delivery in cancer therapy. Oncol Res 1996, 8:28.
65. Felt C, Buri P, Gurny R: Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998, 24:979.
66. Torchilin VP, Trubetskoy VS, Which polymer can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995, 16:141.
67. Storm G, Belliot SO, Daemen T, Lasic DD: Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995, 17:31.
68. Kreuter J: Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2000, 47:65.
69. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307(1):93January Review.
70. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001, 74:317.
71. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol (London, England) 2005, 1(6):779 Review.